Propanc Biopharma (OTCMKTS:PPCB) Ltd is a clinical‐stage biopharmaceutical company focused on the development of novel protein‐based therapeutics for the treatment of hard‐to‐treat cancers. The company’s proprietary technology centers on the delivery of pancreatic proenzymes, including trypsinogen and chymotrypsinogen, which are formulated to target the extracellular matrix and disrupt tumor growth and metastatic progression. Propanc’s lead candidate, PRP, has been evaluated in early‐phase clinical and preclinical studies for indications such as pancreatic, ovarian and colorectal cancers.
Originally founded as TBG Diagnostics Ltd in 2009, the company initially pursued diagnostic platforms for early cancer detection before transitioning to therapeutic development and rebranding as Propanc Biopharma in 2018. Since that strategic shift, Propanc has built a pipeline of protein proenzyme candidates designed to exploit unique mechanisms of action in solid tumors, with a view to addressing the significant unmet medical needs in oncology.
Propanc operates a GMP‐compliant manufacturing facility to support its preclinical and clinical programs, and has established collaborations with research institutions to advance its product candidates through regulatory pathways. The company’s development strategy emphasizes combination studies with standard‐of‐care therapies and expansion into additional tumor types where the tumor microenvironment presents barriers to treatment efficacy.
Headquartered in Sydney, Australia, with additional operations in the United States, Propanc Biopharma is led by a management team with extensive experience in biotechnology and oncology drug development. Under the leadership of Chief Executive Officer Dr. Mark Diamond and a board of directors comprised of seasoned life‐science executives, the company continues to pursue its vision of bringing innovative, protein‐based cancer therapies to patients worldwide.
